GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » Institutional Ownership

SOPH (Sophia Genetics) Institutional Ownership : 27.08% (As of Mar. 26, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sophia Genetics's institutional ownership is 27.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sophia Genetics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sophia Genetics's Float Percentage Of Total Shares Outstanding is 72.85%.


Sophia Genetics Institutional Ownership Historical Data

The historical data trend for Sophia Genetics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics Institutional Ownership Chart

Sophia Genetics Historical Data

The historical data trend for Sophia Genetics can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28
Institutional Ownership 5.16 6.10 6.06 6.10 6.11 6.21 6.28 6.35 6.45 6.43

Sophia Genetics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Sophia Genetics Business Description

Traded in Other Exchanges
Address
La Piece 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.